# An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

> **NCT06443944** · — · AVAILABLE · sponsor: **CG Oncology, Inc.**

## Conditions studied

- Non-Muscle Invasive Bladder Cancer
- Urothelial Carcinoma
- Urologic Cancer
- Bladder Cancer

## Interventions

- **DRUG:** Cretostimogene Grenadenorepvec
- **OTHER:** n-dodecyl-B-D-maltoside

## Key facts

- **NCT ID:** NCT06443944
- **Lead sponsor:** CG Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06443944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06443944, "An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06443944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*